Nixcela Ares-Valdes
Family Medicine · Houston, TXNPI 1902002801
Payments from drug & device makers
Across 127 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$424
- AbbVie$367
- Novo Nordisk$254
- Bayer$192
- AstraZeneca$169
- Astellas Pharma US Inc$106
- plus $656 from 18 others
What the payments were for
- Food & beverage$2,08496%
- Education$854%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 25 | $424 |
| AbbVie(2 entities) | 22 | $367 |
| Novo Nordisk | 16 | $254 |
| Bayer | 12 | $192 |
| AstraZeneca | 9 | $169 |
| Astellas Pharma US Inc | 2 | $106 |
| Merck | 5 | $67 |
| Pfizer | 4 | $61 |
| Amgen(2 entities) | 4 | $60 |
| Ironwood Pharmaceuticals, Inc | 3 | $51 |
| Gilead | 4 | $49 |
| Otsuka America Pharmaceutical, Inc. | 2 | $46 |
| Cipher Pharmaceuticals US LLC | 1 | $46 |
| GSK | 3 | $45 |
| Lilly USA, LLC | 3 | $44 |
| Exact Sciences | 2 | $43 |
| Johnson & Johnson | 3 | $40 |
| Phadia US Inc. | 1 | $23 |
| Abbott | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Cumberland Pharmaceuticals, Inc. | 1 | $12 |
| Vifor Pharma, Inc. | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
How this compares
$2,169 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 63 | $106,565 |
| LinzessLinaclotide | 67 | $92,094 |
| EliquisApixaban | 47 | $90,364 |
| FarxigaDapagliflozin Propanediol | 66 | $77,065 |
| JardianceEmpagliflozin | 47 | $73,348 |
| JanuviaSitagliptin Phosphate | 42 | $65,306 |
| OzempicSemaglutide | 20 | $48,186 |
| GemtesaVibegron | 37 | $44,339 |
| TrulicityDulaglutide | 19 | $37,365 |
| MyrbetriqMirabegron | 26 | $34,649 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $33,408 |
| VascepaIcosapent Ethyl | 42 | $31,582 |
| Icosapent Ethyl | 37 | $19,661 |
| XareltoRivaroxaban | 11 | $16,582 |
| Levemir FlexpenInsulin Detemir | 26 | $14,736 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $44 | $143,93082 claims |
| AbbVieLinzess | $367 | $92,09467 claims |
| PfizerEliquis | $61 | $90,36447 claims |
| AstraZenecaFarxiga | $169 | $77,06566 claims |
| MerckJanuvia | $67 | $65,30642 claims |
| Novo NordiskOzempic | $254 | $48,18620 claims |
| Astellas Pharma US IncMyrbetriq | $106 | $34,64926 claims |
| Johnson & JohnsonXarelto | $40 | $16,58211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Houston
- Lisa HollowayHouston$30.1M
- Veronica FragosoHouston$24.5M
- Bonnie ColvilleHouston$19.6M
- Oscar de ValleHouston$12.8M
- van TranHouston$11M
- Joe PouzarHouston$10.7M
- Aalia Al-BarwaniHouston$6.8M
- Terence ChangHouston$3.3M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.